Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02207114 · ClinicalTrials.gov registry record · NA

Using Biomarkers to Optimize Antibiotic Strategies in Sepsis

A NA study of Sepsis, sponsored by University of Pennsylvania.

Completed
Registry status
NA
Development phase
145
Enrollment target
1
Study location

NCT02207114: Completed NA study of Sepsis, sponsored by University of Pennsylvania.

NCT02207114 is a NA study of Sepsis that has completed, run by University of Pennsylvania. The registered enrollment target is 145 participants, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02207114, a NA study of Sepsis, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
NA
Development phase
145 participants
Enrollment target
1
Study location

Study Summary

The proposed work will provide critical insights into the potential impact of a biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a biomarker-based intervention. Overall, the results of this work will be critical in informing future strategies to eliminate unnecessary antibiotic use and curb the continued rise in antimicrobial resistance.

Primary Outcome

The primary outcome is the duration of antibiotic treatment after enrollment, expressed in days. This variable will focus specifically on the antibiotic agents given for the episode of presumed sepsis for which the patient was included in the study.

Conditions Studied

Interventions

  • OTHER Biomarker Algorithm Intervention

Study Locations (1)

Pennsylvania

  • Hospital of the University of Pennsylvania - Medical Intensive Care Unit - Philadelphia

Trial Details

FieldValue
Enrollment Target 145 participants
Start Date 2012-01
Est. Completion 2023-12
Phase NA
University of Pennsylvania

1,423 total trials

What the finished NCT02207114 record still lists

NCT02207114 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Biomarker Algorithm Intervention is the first listed.

NCT02207114 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02207114 about?

NCT02207114 is a clinical study titled "Using Biomarkers to Optimize Antibiotic Strategies in Sepsis". The proposed work will provide critical insights into the potential impact of a biomarker-based algorithm on reducing unnecessary antibiotic use in different adult and pediatric/neonatal ICU's. This proposal will also assess the costs (or savings) of a biomarker-based intervention. Overall, the resu...

What is the current status of trial NCT02207114?

This trial is currently completed. It is a NA study. The enrollment target is 145 participants. The study started on 2012-01. Estimated completion is 2023-12.

What conditions does trial NCT02207114 study?

This clinical trial studies the following conditions: Sepsis.

What interventions are being tested in trial NCT02207114?

The interventions under investigation include: Biomarker Algorithm Intervention (OTHER).

Who is sponsoring clinical trial NCT02207114?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02207114 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02207114's enrollment target sits among peer trials

145 51st of 90 higher than 40 of 90 other Sepsis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02688959 · 145 participants · NA

    Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)

  • NCT03586609 · 145 participants · Phase 2

    Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

  • NCT03767595 · 145 participants · NA

    ProACT Post-Approval Study

  • NCT03808337 · 145 participants · Phase 2

    Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02207114, the US trial registry maintained by the National Library of Medicine. NCT02207114 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.